Search

Displaying results 8171 - 8180 of 8415 in total
  1. Drug

    Foselutoclax

    go.drugbank.com/drugs/DB21663
    Investigational

    Foselutoclax has a monoisotopic molecular weight of 1158.28 Da.

  2. Drug

    Crotalus adamanteus antivenin

    go.drugbank.com/drugs/DB13893
    Approved

    Crotalus adamanteus antivenin is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus adamanteus (Eastern Diamondback rattlesnake

  3. Drug

    Q-Derp1

    go.drugbank.com/drugs/DB05857
    Experimental

    Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.

  4. Drug

    Nelotanserin

    go.drugbank.com/drugs/DB12555
    Investigational

    Nelotanserin has been used in trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and REM Sleep Behavior Disorder.

  5. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    The decision was based on issues regarding the formulation of the drug.

  6. Drug

    MVA-SARS-2-S

    go.drugbank.com/drugs/DB16432
    Investigational

    MVA is a highly attenuated poxvirus vector[A226603] that has a high-level of biological safety due to its quality of being a non-replicating virus in mammalian hosts[L30458] and is used to develop vaccines

  7. Drug

    SAR445136

    go.drugbank.com/drugs/DB17708
    Investigational

    [A259063] It was formerly investigated for the treatment of beta-thalassemia, and it is currently being investigated for the treatment of sickle cell disease.[L46148]

  8. Drug

    Faxeladol

    go.drugbank.com/drugs/DB20529
    Investigational

    Faxeladol has a monoisotopic molecular weight of 233.18 Da.

  9. Drug

    Flizasertib

    go.drugbank.com/drugs/DB21613
    Investigational

    Flizasertib has a monoisotopic molecular weight of 271.11 Da.

  10. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.